American Journal of Ophthalmology
Volume 145, Issue 6 , Pages 959-965 , June 2008

Clinical Cure of Bacterial Conjunctivitis with Azithromycin 1%: Vehicle-Controlled, Double-Masked Clinical Trial

  • Mark B. Abelson

      Affiliations

    • Ophthalmic Research Associates, North Andover, Massachusetts
    • Schepens Eye Research Institute, Harvard Medical School, Boston, Massachusetts
    • Corresponding Author InformationInquiries to Mark B. Abelson, Schepens Eye Research Institute, Harvard Medical School, 20 Staniford Street, Boston, MA 02114
    • ,
  • Warren Heller

      Affiliations

    • Arizona Center for Clinical Trials, LLC, Phoenix, Arizona
    • ,
  • Aron M. Shapiro

      Affiliations

    • Ophthalmic Research Associates, North Andover, Massachusetts
    • ,
  • Erwin Si

      Affiliations

    • InSite Vision, Inc, Alameda, California.
    • ,
  • Peng Hsu

      Affiliations

    • InSite Vision, Inc, Alameda, California.
    • ,
  • Lyle M. Bowman

      Affiliations

    • InSite Vision, Inc, Alameda, California.
    • ,
  • AzaSite Clinical Study Group

,Accepted 21 January 2008.

References 

  1. Gigliotti F, Williams WT, Hayden FG, et al. Etiology of acute conjunctivitis in children. J Pediatr. 1981;98:531–536
  2. Seal DV, Barrett SP, McGill JI. Aetiology and treatment of acute bacterial infection of the external eye. Br J Ophthalmol. 1982;66:357–360
  3. Hwang DG, Schanzlin , Rotberg MH, Foulks G, Raizman MB Levofloxacin Bacterial Conjunctivitis Place-controlled Study Group. A phase III, placebo controlled clinical trial of 0.5% levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis. Br J Ophthalmol. 2003;87:1004–1009
  4. Centers for Disease Control and Prevention. Pneumococcal conjunctivitis at an elementary school—Maine, September 20–December 6, 2002. MMWR Morb Mortal Wkly Rep. 2003;52:64–66
  5. American Academy of Ophthalmology. Conjunctivitis, Preferred Practice Pattern. San Francisco, California: American Academy of Ophthalmology; 2003;www.aao.org/ppp
  6. Jain R, Danziqer LH. The macrolide antibiotics: a pharmacokinetic and pharmacodynamic overview. Curr Pharm Des. 2004;10:3045–3053
  7. Protzko E, Bowman L, Abelson M, Shapiro A. Phase 3 safety comparisons for 1.0% azithromycin in polymeric mucoadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitis. Invest Ophthalmol Vis Sci. 2007;48:3425–3429
  8. Kardas P, Devine S, Golembesky A, Roberts C. A systematic review and meta-analysis of misuse of antibiotic therapies in the community. Int J Antimicrob Agents. 2005;26:106–113
  9. Kass MA, Hodapp E, Gordon M, et al. Part I (Patient administration of eye drops: interview). Ann Ophthalmol. 1982;14:775–779
  10. Cagle G, Davis S, Rosenthal A, Smith J. Topical tobramycin and gentamicin sulfate in the treatment of ocular infections: multicenter study. Curr Eye Res. 1981–1982;1:523–534
  11. Kowalski RP, Yates KA, Romanowski EG, et al. An ophthalmologist's guide to understanding antibiotic susceptibility and minimum inhibitory concentration data. Ophthalmology. 2005;112:1987
  12. Abelson M, Protzko E, Shapiro A, Garces-Soldana A, Bowman L. A randomized trial assessing the clinical efficacy and microbial eradication of 1% azithromycin ophthalmic solution vs tobramycin in adult and pediatric subjects with bacterial conjunctivitis. Clin Ophthalmol. 2007;1:177–182
  13. Romanowski E, Mah F, Yates K, Kowalski R, Gordon J. The successful treatment of gatifloxacin-resistant Staphylococcus aureus keratitis with Zymar (gatifloxacin 0.3%) in NZW rabbit model. Am J Ophthalmol. 2005;139:867–877
  14. Donnenfeld E, Perry HD, Chruscicki DA, Bitterman A, Cohn S, Solomon R. A comparison of the fourth-generation fluoroquinolones gatifloxacin 0.3% and moxifloxacin 0.5% in terms of ocular tolerability. Curr Med Res Opin. 2004;20:1753–1758
  15. Dutot M, Pouzaud F, Larosche I, Brignole-Baudouin F, Warnet JM, Rat P. Fluoroquinolone eye drop induced cytotoxicity: role of preservative in P2X7 cell death receptor activation and apoptosis. Invest Ophthalmol Vis Sci. 2006;47:2812–2819
  16. Berdy GJ, Abelson MB, Smith LM, George MA. Preservative-free artificial tear preparations (Assessment of corneal epithelial toxic effects). Arch Ophthalmol. 1992;110:528–532
  17. Hand WL, Hand DL. Characteristics and mechanisms of azithromycin accumulation and efflux in human polymorphonuclear leukocytes. Int J Antimicrob Agents. 2001;18:419–425

PII: S0002-9394(08)00081-0

doi: 10.1016/j.ajo.2008.01.019

American Journal of Ophthalmology
Volume 145, Issue 6 , Pages 959-965 , June 2008

Article Tools

* Image Usage & Resolution